Nderitu, Paul
do Rio, Joan M. Nunez
Rasheed, Rajna
Raman, Rajiv
Rajalakshmi, Ramachandran
Bergeles, Christos
Sivaprasad, Sobha
,
Bhende, Pramod
Raman, Rajiv
Rajalakshmi, Ramachandran
Mohan, Viswanathan
Ramasamy, Kim
Das, Taraprasad
Rani, Padmaja K.
Roy, Rupak
Das, Supita
Mohan, Deepa
Narendran, V.
Manayath, George
Anantharaman, Giridhar
Gopalakrishnan, Mahesh
Natarajan, Sundaram
Krishnan, Radhika
Mani, Sheena Liz
Agarwal, Manisha
Padhi, Tapas
Behera, Umesh
Bhattacharjee, Harsha
Barman, Manabjyoti
Chawla, Gajendra
Sen, Alok
Saxena, Moneesh
Sil, Asim K.
Chakabarty, Subhratanu
Cherian, Thomas
Reesha, K. R.
Naigaonkar, Rushikesh
Desai, Abishek
Deshpande, Col Madan
Kulkarni, Sucheta
Conroy, Dolores
Thethi, Jitendra Pal
Ramakrishnan, Radha
Surya, Janani
Funding for this research was provided by:
Global Challenges Research Fund (MR/P027881/1)
Article History
Received: 20 October 2020
Accepted: 14 April 2021
First Online: 4 May 2021
Competing interests
: S. Sivaprasad reports Consultancy and payments for lectures from Bayer, Boehringer Ingelheim, Novartis, Oxurion, Roche, Allergan, Apellis, outside the current study. P. Nderitu has no conflicts of interest to declare. J.M. Nunez do Rio has no conflicts of interest to declare. R. Rasheed has no conflicts of interest to declare. R. Raman has no conflicts of interest to declare. R. Rajalakshmi has no conflicts of interest to declare. C. Bergeles has no conflicts of interest to declare.